Oral Steroids for Vision Issues
- LoveActually
- Family Elder
- Posts: 211
- Joined: Thu May 28, 2009 2:00 pm
- Location: Southern California
- Contact:
Oral Steroids for Vision Issues
I have learned that it's not a good idea to use oral steroids for vision issues and that IV is preferred. I cannot remember the reason for this. LOL! Can some please refresh my memory?
Thanks!
Thanks!
October 29, 2009 - Dx with RRMS
June 22, 2010 - Dx's changed to Devic's (NMO)
January 4, 2011 - Dx w/Syringomyelia T4-T9, Migraines, and Possible MS (again - long story)
June 22, 2010 - Dx's changed to Devic's (NMO)
January 4, 2011 - Dx w/Syringomyelia T4-T9, Migraines, and Possible MS (again - long story)
- LoveActually
- Family Elder
- Posts: 211
- Joined: Thu May 28, 2009 2:00 pm
- Location: Southern California
- Contact:
- elliberato
- Family Member
- Posts: 82
- Joined: Wed Aug 04, 2010 2:00 pm
- Contact:
oral steroids are poison. My last episode only seemed to get worse off the damn things. Its like your damned if you do and damned if you dont. Xanax actually works better for me. My doc never tapered me off iv. Consider doing 1/2 dose IV seems the benefit can be about as good as the full dose without all the anxiety. Boy MS doesnt discriminate does it, you sure are a sight for soar eyes 

- LoveActually
- Family Elder
- Posts: 211
- Joined: Thu May 28, 2009 2:00 pm
- Location: Southern California
- Contact:
Thank you all. I've managed to avoid steroids thus far but there was one time when my neuros NP prescribed me only oral steroids for vision issues. He was not happy about this and explained to me why but I couldn't remember.
October 29, 2009 - Dx with RRMS
June 22, 2010 - Dx's changed to Devic's (NMO)
January 4, 2011 - Dx w/Syringomyelia T4-T9, Migraines, and Possible MS (again - long story)
June 22, 2010 - Dx's changed to Devic's (NMO)
January 4, 2011 - Dx w/Syringomyelia T4-T9, Migraines, and Possible MS (again - long story)
Oral steriods cause Brain Atrophy
Oral steriods cause Brain Atrophy.
jackD
Mult Scler 2002 Oct;8(5):415-9
Cerebral volume changes in multiple sclerosis patients treated with
high-dose intravenous methylprednisolone.
Hoogervorst EL, Polman CH, Barkhof F
Department of Neurology, VU Medical Center, Amsterdam, The
Netherlands.
OBJECTIVE: Multiple sderosis (MS) patients develop varying degrees of
cerebral atrophy, which may already begin at disease onset The
purpose of this study is to examine the effect of steroid treatment
on cerebral volume in MS patients.
METHODS: Thirty-five MS patients
participating in a clinical trial of oral interferon beta, which
induded monthly MRI, were included in this study. They suffered from
an acute relapse and were treated with intravenous methylprednisolone
(IV-MP); 13 of the patients were treated with oral prednisolone
tapering after IV-MP. The last MRI scan before and the first (and
second for oral tapering patients) scan after IV-MP treatment were
used for measuring parenchymal fraction (PF) and ventricular fraction
(VF). Changes in PF and VF were analysed using Student's t test.
RESULTS: For the total population no significant changes in PF or VF
were found.
However, the subgroup of patients receiving oral tapering
after IV-MP showed changes, compatible with atrophy in both PF and
VF, that were significant immediately after IV-MP treatment and still
persisted (though not statistically significant anymore) after a mean
interval of 30 days. The magnitude of these changes was about the
same as the annual change in cerebral volume as reported in natural
history studies.
CONCLUSION: Our data indicate that short courses of
intravenous steroids (restricted to three or five days) have no major
impact, whereas prolonged treatment with oral tapering does
significantly affect brain volume. These findings are important for
longitudinal studies and clinical trials in which brain volume is
used as an outcome measure.
PMID: 12356209, UI: 22243022
jackD
Mult Scler 2002 Oct;8(5):415-9
Cerebral volume changes in multiple sclerosis patients treated with
high-dose intravenous methylprednisolone.
Hoogervorst EL, Polman CH, Barkhof F
Department of Neurology, VU Medical Center, Amsterdam, The
Netherlands.
OBJECTIVE: Multiple sderosis (MS) patients develop varying degrees of
cerebral atrophy, which may already begin at disease onset The
purpose of this study is to examine the effect of steroid treatment
on cerebral volume in MS patients.
METHODS: Thirty-five MS patients
participating in a clinical trial of oral interferon beta, which
induded monthly MRI, were included in this study. They suffered from
an acute relapse and were treated with intravenous methylprednisolone
(IV-MP); 13 of the patients were treated with oral prednisolone
tapering after IV-MP. The last MRI scan before and the first (and
second for oral tapering patients) scan after IV-MP treatment were
used for measuring parenchymal fraction (PF) and ventricular fraction
(VF). Changes in PF and VF were analysed using Student's t test.
RESULTS: For the total population no significant changes in PF or VF
were found.
However, the subgroup of patients receiving oral tapering
after IV-MP showed changes, compatible with atrophy in both PF and
VF, that were significant immediately after IV-MP treatment and still
persisted (though not statistically significant anymore) after a mean
interval of 30 days. The magnitude of these changes was about the
same as the annual change in cerebral volume as reported in natural
history studies.
CONCLUSION: Our data indicate that short courses of
intravenous steroids (restricted to three or five days) have no major
impact, whereas prolonged treatment with oral tapering does
significantly affect brain volume. These findings are important for
longitudinal studies and clinical trials in which brain volume is
used as an outcome measure.
PMID: 12356209, UI: 22243022